Ph.D., Molecular
Biology, University of Maryland Research Associate, Molecular Genetics Section, National Cancer Institute,
NIH, Bethesda, Maryland. Post-Doctoral Fellow, Mammalian Genetics
Laboratory, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland
Selected Publications:
Wu K, Orme L, Shaughnessy J, Jacobson
J, Barlogie B, and Moore MAS. Telomerase and Telomere Length in Multiple Myeloma:
Correlations with Disease Heterogeneity, Cytogenetic Status and Overall
Survival. Blood, 101:4982-4989 (2003)
Tarte K, De Vos J, Zhan F, Klein B, and Shaughnessy J.Gene Expression
Profiling of Plasma Cells and Plasmablasts: Toward a Better Understanding of the
Late Stages of B-Cell Differentiation. Blood, 102:592-600 (2003)
Shaughnessy J.Microarray Profiling of Multiple Myeloma. Int J. Haematol. 77:213-225
(2003)
Shaughnessy J
and Barlogie B. Interpreting the Molecular Biology and Clinical Behavior of
Multiple Myeloma Through Global Gene Expression Profiling. Immunol.
Rev.194:140-63 (2003)
Shaughnessy J Jr.
Primer On Medical Genomics. Part IX: Scientific and Clinical Applications of
DNA Microarrays-Multiple Myeloma As A Disease Model. Mayo Clin Proc.
8:1098-109 (2003)
Zhan F, Barlogie B, and Shaughnessy
J. Toward the Identification Distinct Molecular and Clinical Entities of
Multiple Myeloma Using Global Gene Expression Profiling. Semin. Hematol.
40:308-20 (2003)
Tian E, Zhan F, Walker R, Rasmussan E,
Ma Y, Barlogie B, Shaughnessy J.The Role of the Wnt-Signaling
Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma.
N Eng J Med. 349:2483-2494 (2003)
Shaughnessy J,
Barlogie B, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E,
Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari
M, Jacobson J, Crowley J, Tricot G. Continuous absence of metaphase-defined
cytogenetic abnormalities especially of chromosome 13 and hypodiploidy assures
long-term survival in multiple myeloma treated with Toal Therapy I;
interpretation in the context of global gene expression. Blood,
101:3849-3856. (2003)
Shaughnessy J,
Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas
A, Muwalla F, Morris C, Barlogie B. Prognostic impact of cyotogenetic
and interphase fluorescence in situ hybridization-defined chromosome 13 deletion
in multiple myeloma: early results of Total Therapy II. Br J Hem, 120:44-52.
(2003)
Shaughnessy J,
Barlogie B. Integrating cytogenetics and gene
expression profiling in the molecular analysis of multiple myeloma. Int J
Hematol, 76:59-64. (2002)
Bumm K, Zheng M, Bailey C, Zhan
F, Chiriva–Internati M, Eddlemon P, Terry J, Barlogie B and Shaughnessy J.
CGO: Utilizing and Integrating Gene Expression Microarrays in Clinical
Research and Data-Management. Bioinformatics, 18: 327-328. (2002)
Zhan, F, Hardin, J, Bumm K, Zheng M,
Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla
F, Van Rhee F, Fassas A, Tricot G, Crowley J, Barlogie B, and Shaughnessy J.Global Gene Expression Profiling Of Multiple Myeloma, Monoclonal Gammopathy
Of Undetermined Significance And Normal Bone Marrow Plasma Cells. Blood,
99:1745-1757. (2002)
Shaughnessy J,
Gabrea A, Ying Q, Brents, L, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel PL,
and Kuehl M Cyclin D3 at 6p21 is dysregulated by recurrent Ig translocations
in multiple myeloma. Blood 98:217-223. (2001)
Shaughnessy J,
Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J and
Barlogie B. High Incidence of Chromosome 13 Deletion In Multiple Myeloma
Detected by Multi-Probe Interphase FISH. Blood, 96:1505-1511. (2000)
Having problems
with the site? E-mail the Webmaster.
Copyright 2002-2005, Myeloma Institute for
Research and Therapy, University of Arkansas for Medical Sciences Terms and Conditions of Use
The information on the Myeloma Institute web site
is not intended as a substitute for professional medical attention. The
information is intended only as an aid in understanding current medical
knowledge. A physician should always be consulted for any health concern or
medical condition. The Myeloma Institute web site provides links to other
organizations as a service to our readers. The Myeloma Institute is not
responsible for the information provided on other web sites.
